Total submissions: 7
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
ARUP Laboratories, |
RCV001000618 | SCV001157615 | uncertain significance | Autosomal recessive nonsyndromic hearing loss 77 | 2019-09-16 | criteria provided, single submitter | clinical testing | The LOXHD1 c.1605A>G p.Ile535Met variant (rs770710016), to our knowledge, has not been reported in the medical literature or gene specific databases. This variant is found in the general population with an allele frequency in non-Finnish Europeans of 0.01% (9/77,580 alleles) in the Genome Aggregation Database. The isoleucine at codon 535 is moderately conserved (Alamut v.2.11) and computational analyses (SIFT, PolyPhen-2) predict that this variant is deleterious. Based on the available information, the clinical significance of this variant is uncertain. |
Athena Diagnostics | RCV001289084 | SCV001476664 | uncertain significance | not provided | 2019-12-02 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV001289084 | SCV002190162 | uncertain significance | not provided | 2022-09-21 | criteria provided, single submitter | clinical testing | This sequence change replaces isoleucine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 535 of the LOXHD1 protein (p.Ile535Met). This variant is present in population databases (rs770710016, gnomAD 0.01%). This variant has not been reported in the literature in individuals affected with LOXHD1-related conditions. ClinVar contains an entry for this variant (Variation ID: 811044). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Benign"; Align-GVGD: "Class C0"). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may create or strengthen a splice site. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV001000618 | SCV002788707 | uncertain significance | Autosomal recessive nonsyndromic hearing loss 77 | 2021-07-28 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001289084 | SCV003933360 | uncertain significance | not provided | 2023-10-04 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Ambry Genetics | RCV004639428 | SCV005136604 | uncertain significance | Inborn genetic diseases | 2024-05-30 | criteria provided, single submitter | clinical testing | The c.1605A>G (p.I535M) alteration is located in exon 12 (coding exon 12) of the LOXHD1 gene. This alteration results from a A to G substitution at nucleotide position 1605, causing the isoleucine (I) at amino acid position 535 to be replaced by a methionine (M). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Natera, |
RCV001000618 | SCV002086332 | uncertain significance | Autosomal recessive nonsyndromic hearing loss 77 | 2020-03-04 | no assertion criteria provided | clinical testing |